Natural Killer (NK) cells are a class of cytotoxic lymphocytes with the ability to rapidly eliminate transformed or infected cells upon activation [1] . A key mediator of the NK cell line activity, NKp30, is a member of the natural cytotoxicity receptors (NCRs) that signal pro-inflammatory cytokine and chemokine production, as well as the release of cytotoxic agents that leads to tumor cell death [2] . The active search of NKp30-dependent immunostimulatory ligands led to chemical cross-linking studies followed by tryptic digestion, tandem mass spectrometry and proteomic analyses of the leukemia cell line K562 with soluble NKp30-Fc fusion protein which revealed B7H6 as a cell membrane expressed protein ligand of the NKp30 receptor [3] . Mechanistic studies demonstrated that upon binding of B7H6 to NKp30, the association of a transmembrane arginine residue of NKp30 to an ITAM bearing protein, such as CD3ζ, initiated a signaling cascade that resulted in the reorganization of the NK cells' cytoskeleton and initiation of Ca 2+ flux that ultimately led to the secretion of inflammatory cytokines [4] . Consequently, the discovery of the B7H6-NKp30 binding interaction offers a new opportunity in the development of tumor immunotherapy applications [5] . This study will highlight our most recent achievements in validating B7H6 as a lead protein biologic in cancer immunotherapy.
Introduction
Natural Killer (NK) cells are a class of cytotoxic lymphocytes with the ability to rapidly eliminate transformed or infected cells upon activation [1] . A key mediator of the NK cell line activity, NKp30, is a member of the natural cytotoxicity receptors (NCRs) that signal pro-inflammatory cytokine and chemokine production, as well as the release of cytotoxic agents that leads to tumor cell death [2] . The active search of NKp30-dependent immunostimulatory ligands led to chemical cross-linking studies followed by tryptic digestion, tandem mass spectrometry and proteomic analyses of the leukemia cell line K562 with soluble NKp30-Fc fusion protein which revealed B7H6 as a cell membrane expressed protein ligand of the NKp30 receptor [3] . Mechanistic studies demonstrated that upon binding of B7H6 to NKp30, the association of a transmembrane arginine residue of NKp30 to an ITAM bearing protein, such as CD3ζ, initiated a signaling cascade that resulted in the reorganization of the NK cells' cytoskeleton and initiation of Ca 2+ flux that ultimately led to the secretion of inflammatory cytokines [4] . Consequently, the discovery of the B7H6-NKp30 binding interaction offers a new opportunity in the development of tumor immunotherapy applications [5] . This study will highlight our most recent achievements in validating B7H6 as a lead protein biologic in cancer immunotherapy.
Results and Discussion
Flow cytometry was used to investigate the binding interactions of the soluble free form of B7H6 with the NK92-MI cells known to overexpress the cell surface NKp30 receptor. In a direct binding assay, Alexa Fluor 488-labeled B7H6 demonstrated similar binding to NK92-MI cells' (85%) compared to the human APC-labeled antiNKp30 monoclonal antibody (95%) (Figure 1 ). These initial results confirmed the NK cells' binding affinity of the B7H6 ligand. A competitive binding assay was next conducted in order to determine the NKp30 receptor binding specificities of the B7H6 ligand. In this assay, the NK92-MI cells were incubated with the Alexa Fluor 488-labeled B7H6 ligand, followed by treatment with the APC-labeled antiNKp30 monoclonal antibody. Flow cytometry analyses demonstrated partial displacement of B7H6 (~70%) upon addition of the antiNKp30 monoclonal antibody (Figure 2) . Interestingly, when the NK92-MI cells were first incubated with the APC-labeled antiNKp30 monoclonal antibody, followed by treatment with the Alexa Fluor 488-labeled B7H6 ligand, no displacement was observed, suggesting allosteric binding of both ligands to the NKp30 receptor. Nevertheless, the ability for B7H6 to induce inflammatory responses on the NK92-MI cells was next evaluated by ELISA. In this assay, the NK92-MI cells were left untreated (negative control), and incubated with the soluble free form of B7H6 (test sample). Following a 24 h incubation period, the cells were harvested and media was tested for the secretion of the pro-inflammatory cytokines TNF and IFNIn this assay, B7H6 was found to activate NK92-MI cells resulting in the release of pro-inflammatory cytokines TNF and IFN (Figure 3) . These results supports B7H6 as an immunostimulatory ligand of the NK92-MI cells for the development of cancer-targeted immunotherapy approaches. Moreover, B7H6 will be studied as a synergistic activator of proinflammatory cytokines as well as a trigger of potent immunological activities within diverse tumor microenvironments. 
